R&D Trends

SSB and G-Con form global collaboration

Monday, January 23, 2012 12:27 PM

Sartorius Stedim Biotech (SSB) and G-Con Manufacturing have formed a global collaboration to offer highly advanced and flexible production platforms for the biopharmaceutical manufacturing industry. The new product line will leverage G-Con’s modular, mobile clean-room “pods” and SSB’s broad single-use and reusable product portfolio to create a totally integrated production process platform.

More... »

Genetic and genomic lab testing creates 116,000 U.S. jobs

Friday, January 20, 2012 03:46 PM

Driven by rapid innovation made possible in large part by the mapping of the human genome, genetic and genomic clinical laboratory testing generates 116,000 U.S. jobs and contributes $16.5 billion annually to the U.S. economy, according to a new report by the Battelle Memorial Institute.  Because this industry sector is still in the early stages of development, according to the report, much future growth is expected to occur.

More... »

Novartis to restructure, cut 1,960 jobs

Thursday, January 19, 2012 09:30 AM

Novartis has announced plans to strengthen its long-term competitive position and reduce its cost base with a restructuring of U.S. operations.

More... »

Covance enters R&D collaboration

Thursday, January 19, 2012 08:30 AM

Covance, Inserm Transfert, a subsidiary of Inserm, and seed investment company Inserm Transfert Initiative have signed a four-year R&D collaboration.

More... »

BioCity Scotland secures former MSD site

Wednesday, January 18, 2012 12:09 PM

Newly-formed BioCity Scotland, a centralized base for growing bioscience, pharameutical, med tech and health companies, will set up house in the former-MSD research facility at Newhouse, which it acquired Jan. 11.

More... »

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

More... »

Children benefit from nearly 300 meds in development

Friday, January 13, 2012 01:42 PM

Today, a whopping 282 medicines to treat children and adolescents are in clinical trials or under review by the FDA, according to a report by Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

J&J closes Quebec research center

Wednesday, January 11, 2012 01:12 PM

Johnson & Johnson is closing its Quebec research center, according to a news report on Canada.com.

More... »

KalVista, JDRF partner to treat diabetic eye disease

Wednesday, January 11, 2012 11:23 AM

KalVista Pharmaceuticals has enlisted the help of the Juvenile Diabetes Research Foundation (JDRF) to further a novel approach KalVista is developing to preserve vision and slow progression of eye disease in type 1 diabetics.

More... »

Biogen Idec announces 2012 goals

Wednesday, January 11, 2012 11:15 AM

Growing its leadership position in multiple sclerosis (MS), advancing its late-state pipeline, leveraging R&D capabilities to grow its early-stage pipeline and preparing for potential launches of new high-impact therapies are among Biogen Idec’s recently announced 2012 strategic priorities.

More... »